{"id":"NCT00974571","sponsor":"Organon and Co","briefTitle":"Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)","officialTitle":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-11","primaryCompletion":"2002-05","completion":"2002-05","firstPosted":"2009-09-10","resultsPosted":"2010-06-07","lastUpdate":"2022-02-03"},"enrollment":1365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"montelukast sodium","otherNames":[]},{"type":"DRUG","name":"Comparator: cetirizine","otherNames":[]},{"type":"DRUG","name":"Comparator: placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the ability of montelukast to improve the signs and symptoms of perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an active control.","primaryOutcome":{"measure":"Mean Change From Baseline in Daytime Nasal Symptoms Score","timeFrame":"Baseline and first 4 weeks of a 6-week treatment period","effectByArm":[{"arm":"Montelukast 10 mg","deltaMin":-0.39,"sd":null},{"arm":"Cetirizine 10 mg","deltaMin":-0.45,"sd":null},{"arm":"Placebo","deltaMin":-0.36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17619558"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":630},"commonTop":["Headache","Upper Respiratory Infection"]}}